Skip to content
  • 6.06.2025
  • Imprint
  • Contact
  • Privacy

Health News

Daily Health News

  • Homepage
  • Technology
  • Journal
  • Economy
  • Science
  • Education
Education

Accuray Announces FDA Approval For Vitahold

2023-08-14


VitaHold facilitates maximum reproducible breath-holding. DIBH treatments help to minimise radiation doses to organs at risk, while reducing complications later in life. During treatment, the patient's heart is moved away from the chest wall and the targeted tumour, allowing breathing. Your automated surface-guided radiation monitoring position continuously monitors breathing and positions in the cameras for radiation delivery. This method allows care teams to effectively position the patient and confidently monitor their accuracy. "Our goal in offering VitalHold for the Radixact System is to give clinicians additional choice and flexibility when treating all the breast cancer cases they see every day in their practice," said Suzanne Winter, President and CEO of Accuray. "Now Accuray can offer our customers the widest range of radiation therapy delivery techniques in a single device, the Radixact System. This industry-leading approach demonstrates how our relentless focus on innovation is making Accuray's already great system even better, providing clinicians with tools that help ensure precise, truly personalised treatments are available to more patients."

Radixact ensures precise delivery of radiation to any tumour bed during each treatment, while minimising doses to nearby healthy organs and tissues. It allows radiation therapy as a treatment option for breast cancer at almost any stage. Areas of use include post-operative, chemotherapy and other drugs.

Redixact, a CT Linac-Based system, provides multiple radiation delivery options to tailor treatment to the patient's needs, enabling clinicians to treat breast cases in as little as two minutes. The system's TomoHelical mode continuously delivers radiation beams around the patient. This feature realises the treatment of complex cases such as breast cancer and cancer in the surrounding lymph nodes.

"You can be sure that it will touch the lives of countless breast cancer patients"

Cecilia de Leeuw, CEO and president of C-RAD, said, "C-RAD is incredibly proud of our collaboration with Accuray. Together, we have created a seamless integration between our systems to ensure the highest level of accuracy and efficiency for breast cancer treatment." "VitalHold is a powerful application of C-RAD's proven SGRT technology and is sure to touch the lives of countless breast cancer patients."






Education

 

Copyright © 2022 Health News